# Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

> **NCT03774901** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 32 (estimated)

## Conditions studied

- Penile Cancer
- Penile Neoplasms
- Penile Squamous Cell Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03774901
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-12
- **Primary completion:** 2024-09-22
- **Final completion:** 2024-09-22
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774901, "Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03774901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*